Introduction

Incidence and risk factors
The incidence of post-transplant lymphoproliferative Solid organ transplant recipients are at a greatly increased risk of lymphoproliferative tumours. The disease (PTLD) in renal transplant recipients is of the order of 1% [1] : a risk of lymphoma approximately majority is of B cell origin and has been shown to contain the Epstein-Barr virus ( EBV ) genome and twenty times greater than that seen in the general population. The major risk factor for PTLD in solid express viral proteins on the cell surface. The virus attaches to the C3d complement component receptor organ transplantation is the degree of immunosuppression. A high incidence of PTLD was seen following so effects are confined to cells that carry this receptor. These are squamous epithelial cells of the oropharynx the introduction of cyclosporin A, which was greatly reduced after drug level monitoring became widespread and B-lymphocytes. In the latter cell a latent infection and dose reduction occurred to about one fifth of that occurs. The virus has the capability of transforming initially used [2] . The incidence of PTLD with tacrolthese cells into continuously growing immortalized imus is probably comparable to that seen with lymphoblastoid lines. cyclosporin A [3] . The risk is much increased following antibody treatment [1] . The therapeutic suppression of natural cytotoxic T-cell activity is likely to be the cause of uncontrolled EBV-driven proliferation of B-cells [4] . Initially, poly- with a growth advantage will predominate as time passes. Cyto-megalo-virus (CMV ) disease increases the phenolate is advised, as is the reduction of prednisolone to approximately 10 mg per day. Cyclosporin A or risk of subsequent PTLD approximately 7-fold in liver transplant recipients [5] . The primary infection that is tacrolimus can be reduced in a step-wise fashion by about one fifth every 2 weeks. Patients need to be seen in a sero-negative recipient of a sero-positive graft is an important risk factor for PTLD with a relative closely monitored, both for evidence of graft rejection as well as tumour growth or regression. It is common risk ratio of 76-fold increased in that situation; this is a particular problem in paediatric practice [6 ] .
to stop cyclosporin A or tacrolimus dose reduction when approximately 30% of the initial dose is reached. Remission has been achieved with interferon alpha
The modes of clinical presentation in a number of cases [13] but as the treatment regimens are complicated and the number of patients treated small it is difficult to be sure of the value of this PTLD is heterogenous, but most cases can be divided into one of four syndromes. An acute infectious mono-approach.
Recently there have been efforts directed towards nucleosis-like disease with marked constitutional upset and rapid enlargement of tonsils and cervical nodes estimating viral load. Because of technical considerations there is particular interest in quantifying EBV is the most typical pattern in the first year posttransplantation. A fulminant presentation can occur DNA in serum rather than peripheral blood lymphocytes and a sensitivity of 83% and specificity of 100% within weeks of transplantation and presents with widespread infiltrative disease with multi-organ for one such test has been reported [14] . Given that the rise in EBV viral load can be detected by serial involvement with a grave prognosis. The first two presentations are more common in young recipients measurements prior to PTLD, there is interest in monitoring, allowing pre-emptive prophylaxis and who are sero-negative and receive a sero-positive organ. Isolated or multiple tumours, the latter often avoiding PTLD. Unfortunately the optimal prophylactic strategy is far from clear. The reliability of viral involving the allograft and on occasions mistaken for rejection, are usual more than 1 year post-grafting. load estimation to aid the fine adjustment of immunosuppressive medication is yet to be determined. In The presentation is usually of indolent disease and visceral, nodal, and extra-nodal tumours are the rule. particular, the author's point out that rebound of the viral load is common but relapse of PTLD relatively Gastrointestinal involvement is relatively common, as are pulmonary nodules; the lung may be the only site rare at less than 10% [15] .
Although intravenous gancyclovir or acyclovir will involved. EBV-negative B cell PTLD occurs in approximately 10% of cases. This is usually of late onset and inhibit the lytic phase and decrease the degree of oropharyngeal shedding of virus [16 ] , the number of clinically resembles non-Hodgkin's lymphoma.
Clinical features do not correlate with the histo-EBV infected cells in peripheral blood is not altered by acyclovir treatment [17] . The anti-viral drugs only logical classification. As more sensitive techniques have been employed it has been appreciated that tissue inhibit lytic infection and typically only about 1% of the cells infected are in a lytic phase. Anti-viral drugs found to be polyclonal by immunophenotyping contains monoclonal sub-populations [7] . Similarly, as would not be expected to influence the immortalized B-cells that are responsible for the PTLD syndrome. techniques have improved, the percentage of tumours shown to contain EBV has increased. The pathology Consistent with this is the observation by several authors that viral loads increase while patients are and classification have recently been reviewed and summarized [8] .
receiving acyclovir or gancyclovir [17] . However, it is possible, but unproven, that inhibiting the lytic phase may influence progression of PTLD. Acyclovir, valacy-
Managing the patient with PTLD
clovir and gancyclovir have only weak, foscarnet good, and cidovir high in vitro activity against EBV. Antiviral drugs that are active against CMV may have In children receiving orthotopic liver transplants reactivation of EBV may be coincident with PTLD. some effect in PTLD as CMV produces B-cell stimulating cytokines. The literature on anti-viral treatment in However, a large proportion, perhaps as much as 90%, of PTLD in the first year is triggered by a primary PTLD has recently been reviewed [18] , but the reports are confused and the drugs appear to offer EBV infection that occurs within 4 months of a seronegative recipient receiving a sero-positive graft [9] . relatively little anti-tumour effect. Unlike non-Hodgkin lymphoma in general, PTLD can be cured by surgical Where possible avoiding such mismatches, especially in high-risk groups, is a sensible tactic. There has been excision or irradiation of strictly localized lesions. This approach should be considered in these circumstances recent research aimed towards achieving a vaccine directed against an envelope glycoprotein (gp340) [10] [19] . Another approach is to use passive immunization with anti-EBV antibody [20] . Anti-B-cell monoclonal and a latent membrane protein [11] .
The mainstay of management is the drastic reduction antibodies are an attractive treatment option and were found to be successful in a European multi-centre trial or cessation of immunosuppressive treatment [12] . This allows the recovery of the recipient's cytotoxic [21] . They are not immunosuppressive; the antigens targeted are such that they deplete the EBV infected T-cell-directed EBV surveillance mechanism. In renal transplantation withdrawal of azathioprine or myco-cell pool and these cells are then lysed by antibody The dose schedule and efficacy has yet to be reported. 
